UnknownPhase 2NCT03932266

Endostar Combined With Induction Chemotherapy and Concurrent Chemoradiotherapy for Locoregional Nasopharyngeal Carcinoma

Studying Nasopharyngeal carcinoma

Last synced from ClinicalTrials.gov

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
Jiangsu Cancer Institute & Hospital
Principal Investigator
Xia He, M.D., Ph.D.
Jiangsu Cancer Institute & Hospital
Intervention
Endostar(drug)
Enrollment
73 target
Eligibility
18-70 years · All sexes
Timeline
20192023

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT03932266 on ClinicalTrials.gov

Other trials for Nasopharyngeal carcinoma

Additional recruiting or active studies for the same condition.

See all trials for Nasopharyngeal carcinoma

← Back to all trials